Samsung Bioepis (Samsung Epis) announced on the 21st that it has launched the first phase of global clinical trials for its 11th biosimilar pipeline 'SB27 (Kitruda).
According to Samsung Epis, it has recruited 135 non-small cell lung cancer test subjects who voluntarily participated in four countries, including Korea, and started phase 1 clinical trials to compare SB27 with the pharmacokinetics, efficacy, and safety of the original drug.
KEYTRUDA is an immuno-oncology drug used for melanoma, non-small cell lung cancer, and head and neck cancer sold by the US multinational pharmaceutical company MSD.
Annual global sales reached approximately 26.3 trillion won in 2022.
Hong Il-sun, managing director of Samsung Epis, said, "Based on the global clinical operation know-how accumulated so far, we will do our best to complete clinical trials in a timely manner," adding, "Through this, we will try to provide patients with various treatment options as soon as possible."
Meanwhile, Samsung Epis will have a total of 11 biosimilar products and pipelines with SB27's entry into phase 1 clinical trials, including seven products sold in global markets such as Europe and three clinical completion pipelines.
[WIKI KOREA=Cho Eun, Reporter]
choeun@wikileaks-kr.org
